Transplantation of hematopoietic progenitor cells from red cell-incompatible donors occurs
in 30–50% of patients. Immediate and delayed hemolytic transfusion reactions are expected …

The independent genomic inheritance of the human leukocyte antigen (HLA) and the ABO-
blood group system allows for HLA-matched hematopoietic progenitor cell transplantation …

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety
of malignant and non-malignant hematological and congenital diseases. Due to the fact that …

Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival
after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We …

The management of hemotherapy in 31 cases of ABO‐or Rh‐incompatible bone marrow
transplantation is described. Our experience confirms that ABO or Rh incompatibility does …

Hemolysis may occur during infusion of an ABO-incompatible HSC component if the
recipient has isoagglutinins directed against donor red blood cells, or later as a result of the …

BACKGROUND: Most studies indicate that ABO incompatibility has no effect on the clinical
outcome after allogeneic peripheral blood progenitor cell (PBPC) transplantation (allo …

BACKGROUND: Graft ABO incompatibility has not been thought to aflect patient survival
after allogeneic bone marrow transplantation, although it may be associated with prolonged …

Hematopoietic progenitor cell (HPC) transplantation has long been established as the
optimal treatment for many hematologic malignancies. In the setting of allogenic HLA …

Aside from causing hemolytic reactions the ABO blood group system does not have an
impact on outcome after allogeneic bone marrow or peripheral blood stem cell …